These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 1349553)

  • 21. Bismuth-based combination therapy for Helicobacter pylori-associated peptic ulcer disease (metronidazole for eradication, ranitidine for pain).
    Tefera S; Berstad A; Bang CJ; Nysaeter G; Hatlebakk JG; Olafsson S; Nesje LB; Hausken T; Berstad K; Hundal O
    Am J Gastroenterol; 1996 May; 91(5):935-41. PubMed ID: 8633584
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The role of Helicobacter pylori in peptic ulcer disease.
    O'Connor HJ
    Scand J Gastroenterol Suppl; 1994; 201():11-5. PubMed ID: 8047817
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Is maintenance acid suppression necessary to reduce the rate of reinfection with Helicobacter pylori?
    Alzoubi K; Rashdan A; Al-Dayyat A; Al-Safi S
    Hepatogastroenterology; 2007 Dec; 54(80):2406-9. PubMed ID: 18265676
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Drugs for peptic ulcer disease and GERD.
    Treat Guidel Med Lett; 2011 Sep; 9(109):55-60; quiz 2 p following 60. PubMed ID: 21860368
    [No Abstract]   [Full Text] [Related]  

  • 25. Current indications for acid suppressants in Helicobacter pylori -negative ulcer disease.
    Howden CW; Leontiadis GI
    Best Pract Res Clin Gastroenterol; 2001 Jun; 15(3):401-12. PubMed ID: 11403535
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immediate eradication of Helicobacter pylori in patients with previously documented peptic ulcer disease: clinical and economic effects.
    Fendrick AM; McCort JT; Chernew ME; Hirth RA; Patel C; Bloom BS
    Am J Gastroenterol; 1997 Nov; 92(11):2017-24. PubMed ID: 9362183
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Peptic ulcer disease: defining the treatment strategies in the era of Helicobacter pylori.
    Hunt RH
    Am J Gastroenterol; 1997 Apr; 92(4 Suppl):36S-40S; discussion 40S-43S. PubMed ID: 9127625
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Drug therapy of peptic ulcer disease.
    Ching CK; Lam SK
    Br J Hosp Med; 1995 Jul 12-Aug 15; 54(2-3):101-6. PubMed ID: 7551483
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-effectiveness of treatment regimens for the eradication of Helicobacter pylori in duodenal ulcer.
    Vakil N; Fennerty MB
    Am J Gastroenterol; 1996 Feb; 91(2):239-45. PubMed ID: 8607487
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Satellite symposium: New therapeutic approach to peptic ulcer disease. 34th annual meeting of the Japanese Society of Gastroenterology.
    Gastroenterol Jpn; 1993 May; 28 Suppl 5():191-201. PubMed ID: 8103024
    [No Abstract]   [Full Text] [Related]  

  • 31. [Effect of maintenance therapy by H2RA on the recurrence of gastric and duodenal ulcer and on the occurrence of reflux esophagitis, gastric erosions, and duodenal erosions after H. pylori eradication].
    Maeyama S; Yoshihara H; Kamada T; Kubota S; Kobayashi I; Tsuji S; Kawano S
    Nihon Rinsho; 2005 Nov; 63 Suppl 11():512-5. PubMed ID: 16363591
    [No Abstract]   [Full Text] [Related]  

  • 32. [Eradication of Helicobacter pylori in peptic ulcer and chronic gastritis. A randomized clinical trial].
    Rodríguez Hernández H; Sánchez Anguiano LF; Quiñones E
    Rev Gastroenterol Mex; 1998; 63(1):21-7. PubMed ID: 10068745
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Drugs for treatment of peptic ulcers.
    Dajani EZ; Trotman BW
    J Assoc Acad Minor Phys; 1992; 3(3):78-88. PubMed ID: 1353999
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [The attitude of primary health care physicians in the metropolitan area of Barcelona about the diagnosis and treatment of Helicobacter pylori infection in gastroduodenal diseases].
    Martínez-Sánchez G; Saperas E; Benavent J; Mearin F; Piñol JL; Barenys M; Mascort JJ; Forné M; Bordas JM; Azagra R; Piqué JM
    Gastroenterol Hepatol; 1998 Dec; 21(10):473-8. PubMed ID: 9927791
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Medical therapy of peptic ulcer: problems and prospects].
    Trabucchi E; Foschi D; Belloli P; Montorsi F; Marchetti V; Mariscotti C; Diamantini S
    Minerva Dietol Gastroenterol; 1989; 35(1):1-6. PubMed ID: 2566959
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High IgE serum levels and "peptic" ulcers: clinical and functional approach.
    De Lazzari F; Mancin O; Plebani M; Venturi C; Battaglia G; Vianello F; Galliani EA; Di Mario F; Naccarato R
    Ital J Gastroenterol; 1994; 26(1):7-11. PubMed ID: 7912969
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A 3-day anti-Helicobacter pylori therapy is a good alternative for bleeding peptic ulcer patients with Helicobacter pylori infection.
    Hsieh YH; Lin HJ; Tseng GY; Perng CL; Chang FY; Lee SD
    Hepatogastroenterology; 2001; 48(40):1078-81. PubMed ID: 11490804
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Effect of acid suppression in subjects with Helicobacter pylori infection].
    Fujisawa T; Adachi K; Kinoshita Y
    Nihon Rinsho; 2005 Nov; 63 Suppl 11():387-90. PubMed ID: 16363565
    [No Abstract]   [Full Text] [Related]  

  • 39. Treatment of peptic ulcer in the elderly. Proton pump inhibitors and histamine H2 receptor antagonists.
    Lazzaroni M; Bianchi Porro G
    Drugs Aging; 1996 Oct; 9(4):251-61. PubMed ID: 8894523
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Quality of healing in peptic ulcer disease--are H2 receptor antagonists all we need?
    Korman MG
    Gastroenterol Jpn; 1993 May; 28 Suppl 5():168-71. PubMed ID: 8103021
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.